In this episode, we focus on the personal journey of Sheila Gujrathi, a physician turned biotech builder whose career spans medicine, big pharma, rapid IPOs, and billion dollar exits. We explore what it takes to raise biotech across cycles, from early clinical development to public markets, and how Sheila navigated building companies while operating in environments where she was rarely the default. Surani speaks with Sheila about growing up as the child of Indian immigrant physicians, making unconventional career decisions, and learning to balance patients, capital, and leadership under pressure. They discuss her time at Genentech and Bristol Myers Squibb, her role in scaling Receptos through IPO and a $7.2 billion acquisition, the founding and listing of Gossamer Bio, and how those experiences shaped her perspective on leadership and led to her writing The Mirror Effect. 00:00: Introduction 01:45: Growing up as the child of Indian immigrant physicians and early expectations around medicine 04:50: Loss, identity, and the year in India that helped shape a personal North Star going into Medical School 10:30: Leaving clinical medicine and stepping into consulting and industry 15:45: Joining Receptos, building from the ground up, and the road to IPO and acquisition 22:50: Founding Gossamer Bio, raising private capital, and going public in just over a year 30:10: Reflection, writing The Mirror Effect, and building pathways for the next generation For more on Sheila's Book, click here For any comments, questions or feedback you can connect directly with Surani Fernando on LinkedIn or email: raisingbiotech@gmail.com Title music composed by: Yrii Semchyshyn (Coma Media)
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
S4, E4: The Weight of the Moment: How GLP-1s are Rewiring Biotech Investing, Expert Analysis
S4, E3: Inside Opus Genetics’ Pivot – Skepticism, Proxy Fights and a Comeback, with CEO George Magrath
S4, E1: From the Archive - Revisiting eGenesis and Xenotransplantation with Pig Organs, Two Years On
S3, E6: Veradermics puts hair loss back on the investor agenda with $150 million Series C - with CEO Dr Reid Waldman and InThought's Julie Hoggatt
Free AI-powered recaps of Raising Biotech and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.